08:16 AM EDT, 10/21/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday it is adding three cancer centers to its Phase 3 clinical study, and expects to report top-line data as early as the first half of next year.

The three centres are Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University.

The Phase 3 study is evaluating BriaCell's lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician's choice of treatment in advanced metastatic breast cancer

Interim data will be analyzed once 144 patient deaths occur, comparing the overall survival in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice as the primary endpoint, a statement said. Positive results of the Phase 3 study could result in full approval and marketing authorization for Bria-IMT in metastatic breast cancer patients. The Bria-IMT combination regimen has already received FDA Fast Track designation.

The company earlier today reported that it is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the clinical development of Bria-OTS+, its personalized off-the-shelf: immunotherapy, for multiple cancer indications including metastatic breast cancer.

BriaCell, which was accepted into MSK's Therapeutics Accelerator 2025 cohort program last August, said the collaboration starts with manufacturing, drug development and clinical protocol support for a Phase 1 clinical trial with Bria-BRES+, its personalized immunotherapy for patients with breast cancer under the Bria-OTS+ platform.

BriaCell shares are flat at $0.60, in New York trading.